When Congress resumes next month, the BioSecure Act will be one of its top priorities. The bill, which could dramatically reorder the global pharmaceutical supply chain, is the latest example of the U.S. trying to exorcize China from its supply chains, and it will have a profound effect on WuXi Apptec, the most important drugmaker American patients have never heard of.